Clinical study of sacubitril/valsartan in the treatment of chronic heart failure
Objective:The aim of this article was to study the clinical curative effect of sacubitril/valsartan in chronic heart failure.Methods:A total of 76 patients with chronic heart failure admitted to the hospital were enrolled between January 2020 and December 2022.According to random number table method,they were divided into observation group and control group,38 cases in each group.On basis of routine regimen,control group was treated with enalapril,while observation group was treated with sacubitril/valsartan.The clinical curative effect after treatment,cardiogram indexes[left ventricular fractional shortening(LVFS),left ventricular eject fraction(LVEF),left ventricular end diastolic diameter(LVEDD],cardiac function related serological indexes[N-terminal brain natriuretic peptide(NT-proBNP),creatine kinase isoenzyme(CK-MB),cardiac troponin I(cTnT)],exercise tolerance[6 minutes walking test(6MWT)]and incidence of adverse reactions before and after 12 weeks of treatment in the two groups were observed.Results:The curative effect of observation group was better than that of control group(P<0.05).After treatment,LVFS and LVEF in observation group were higher than those in control group,while LVEDD was lower than that in control group(P<0.05).After treatment,CK-MB in observation group was higher than that in control group,while NT-proBNP and cTnT were lower than those in control group(P<0.05).After treatment,6MWT results in observation group were better than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The curative effect of sacubitril/valsartan is good in chronic heart failure,which can significantly improve cardiogram indexes,cardiac function related serological indexes and enhance exercise tolerance,with low incidence of adverse reactions.
NETL
NSTL
万方数据
